These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11366145)

  • 1. Patients sought for ACTU studies that will help answer questions about drugs.
    Fac Notes (New Orleans La); 1998; 10(6):6. PubMed ID: 11366145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trials for protease failure.
    Posit Aware; 1998; 9(5):16-7. PubMed ID: 11365884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental drug available.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LaCARP seeks patients for study that will compare protease inhibitors.
    Fac Notes (New Orleans La); 1998; 10(6):6. PubMed ID: 11366144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amprenavir (Agenerase) now available in expanded access.
    AIDS Treat News; 1998 Oct; (No 304):5. PubMed ID: 11365864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harvard/Boston City Medical Center AIDS Clinical Trials Unit.
    Posit Dir News; 1998; 10(2):35-9. PubMed ID: 11365552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
    [No Abstract]   [Full Text] [Related]  

  • 11. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amprenavir approved.
    STEP Perspect; 1999; 99(2):8. PubMed ID: 11366753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study: new drug doesn't display cross-resistance.
    AIDS Alert; 1999 Jul; 14(7):77. PubMed ID: 11366418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosamprenavir: drug development for adherence.
    Hester EK; Chandler HV; Sims KM
    Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded access program begins.
    Highleyman L
    BETA; 1998 Oct; ():3. PubMed ID: 11365989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.
    Prescrire Int; 2001 Jun; 10(53):70-2. PubMed ID: 11718166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
    J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LaCARP opens clinical trials to patients of all primary care providers.
    Fac Notes (New Orleans La); 1998; 10(2):9. PubMed ID: 11365129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.